DEVELOPMENT AND IN VITRO EVALUATION OF SOLID DISPERSIONS OF CANDESARTAN CILEXETIL

Authors

  • UPPULURU ASHOK KUMAR
  • GANDE SURESH

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i2.30597

Keywords:

Candesartan cilexetil, Hypertension, Solid dispersions, Soluplus, Poloxamer, Kolliwax

Abstract

Objective

The main objective of the present study is systematic development of solid dispersions of Candesartan cilexetil by solvent evaporation method to enhance the solubility and bioavailability.

Methods

In the present study, eighteen formulations of solid dispersions were prepared with 1:1 and 1:3 ratios of drug: carrier and with and without surfactant. There was significant improvement in the rate of drug release from all 20 solid dispersions and the formulation (SD16) comprising Candesartan: containing Soluplus (1:3 ratio of drug:  Soluplus with 2% SLS as surfactant) by solvent evaporation process.

Results

Final optimized design SD16 contained maximum drug content of 99.08%. In in vitro dissolution studies it shows greater dissolution rate i.e. 99.7±4.2% associated through additional designs and pure drug. The drug was compatible with all the excipients as per FTIR (Fourier transform infrared spectroscopy). From powder X-ray diffraction (p-XRD) and by (SEM) studies it was evident that crystalline form of Candesartan has been converted into amorphous form within solid dispersion design. 

Conclusion

From these studies we can accomplish solid dispersions are one of the greatest favorable formulation for Candesartan cilexetil for enhancing the solubility and bioavailability of poorly water soluble drugs in the effective group of hypertension and other cardiac problems.

Downloads

Download data is not yet available.

References

Aboul FK, Allam AA, El-Badry M, El-Sayed AM. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil. Eur J Pharm Sci 2017; 15(109):503-513.

Shafiq S, Shakeel F, Talegaonkar S, Ahmad F, Khar R, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm 2007; 66: 227–243.

Pathak K, Raghuvanshi S. Oral bioavailability: Issues and solutions via nano formulations. Clin. Pharmacokinet 2015; 54:325–357.

Kasturi M, Agarwal S, Yadav JK. Self nano-emulsifying drug delivery system of ramipril: formulation and in-vitro evaluation. Int J of Phar and Phar Sci 2016; 8(4): 0975-1491.

Ali HH, Hussein AA. Oral solid self-nanoemulsifying drug delivery systems of candesartan citexetil: formulation, characterization and in vitro drug release studies. Apps open 2017; 3(6).

Patel TB, Patel LD, Patel TB, Makwana SH, Patel TR. Formulation and characterization of Solid Dispersions containing Glibenclamide. International journal of pharmacy and pharmaceutical sciences 2010; 2(3): 0975-1491.

Anna B, Harisha KM, Uday KG. Development, Characterization and Evaluation of Solid dispersions of Artemether and Lumefantrine by solvent evaporation method using hydrophilic polymer. Int J of Phar and Phar Sci 2014; 6(2): 0975-1491.

Yamashita K, Nakate T and Okimoto K. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003; 267: 79-91.

Dasi S and Roy S. Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs. Int J Pharmacol Pharm Tech 2008; 3: 227-24.

Chen S, Zhu J, Ma F, Fang Q, Li Y. Preparation and characterization of solid dispersions of dipyridamole with a carrier "copolyvidonum Plasdone S-630". Drug Dev Ind Pharm 2007; 33(8): 888-99.

Lakshmi K, Reddy MPK, Kaza R. Dissolution enhancement of telmisartan by surface solid dispersion technology. International Journal of Innovative Pharmaceutical Research 2012; 3(4): 247-251.

Shingala K, Chetan S, Deepak D. Formulation development and evaluation of immediate release tablet of poorly soluble candesartan cilexetil. Journal of Pharmaceutical science and Bioscientific Research 2013; 3 (2):77-90.

Valizadeh H, Nokhodchi A, Qarakhani N. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev IndPharm. 2004; 30(3):303-17.

Yang M, Wang P, Huang CY. Solid dispersion of acetaminophen and poly(ethylene oxide) prepared by hot-melt mixing. Int J Pharm 2010; 395(1-2):53-61.

Shamma RN, Basha M. Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation. Powder Technology 2013; 237: 406–414.

Breitenbach J. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 2002; 54: 107–117.

Dhirendra K, Lewis S, Udupa N. Solid Dispersions: A Review. Pak. J. Pharm. Sci 2009. 22(2):234-246.

Published

07-02-2019

How to Cite

KUMAR, U. A., and G. SURESH. “DEVELOPMENT AND IN VITRO EVALUATION OF SOLID DISPERSIONS OF CANDESARTAN CILEXETIL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 12, no. 2, Feb. 2019, pp. 233-41, doi:10.22159/ajpcr.2019.v12i2.30597.

Issue

Section

Original Article(s)